133 related articles for article (PubMed ID: 7701875)
1. Skin scoring in systemic sclerosis: a modification--relations to subtypes and the aminoterminal propeptide of type III procollagen (PIIINP).
Zachariae H; Bjerring P; Halkier-Sørensen L; Heickendorff L; Søndergaard K
Acta Derm Venereol; 1994 Nov; 74(6):444-6. PubMed ID: 7701875
[TBL] [Abstract][Full Text] [Related]
2. Plasma endothelin and the aminoterminal propeptide of type III procollagen (PIIINP) in systemic sclerosis.
Zachariae H; Heickendorff L; Bjerring P; Halkier-Sørensen L; Søndergaard K
Acta Derm Venereol; 1994 Sep; 74(5):368-70. PubMed ID: 7817674
[TBL] [Abstract][Full Text] [Related]
3. Serum aminoterminal propeptide of type III procollagen in progressive systemic sclerosis and localized scleroderma.
Zachariae H; Halkier-Sørensen L; Heickendorff L
Acta Derm Venereol; 1989; 69(1):66-70. PubMed ID: 2563612
[TBL] [Abstract][Full Text] [Related]
4. Serum aminoterminal propeptide of type III procollagen in systemic sclerosis. A follow-up--investigations in subclasses and during therapy.
Heickendorff L; Parvez A; Bjerring P; Halkier-Sørensen L; Zachariae H
Acta Derm Venereol; 1991; 71(3):185-8. PubMed ID: 1678217
[TBL] [Abstract][Full Text] [Related]
5. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
6. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis.
Heickendorff L; Zachariae H; Bjerring P; Halkier-Sørensen L; Søndergaard K
J Am Acad Dermatol; 1995 Apr; 32(4):584-8. PubMed ID: 7896946
[TBL] [Abstract][Full Text] [Related]
7. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis.
Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S
Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918
[TBL] [Abstract][Full Text] [Related]
9. Increased levels of type I and III collagen and hyaluronan in scleroderma skin.
Søndergaard K; Heickendorff L; Risteli L; Risteli J; Zachariae H; Stengaard-Pedersen K; Deleuran B
Br J Dermatol; 1997 Jan; 136(1):47-53. PubMed ID: 9039294
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of aminoterminal type III procollagen peptide and hyaluronan predict mortality in systemic sclerosis.
Scheja A; Akesson A; Hørslev-Petersen K
Scand J Rheumatol; 1992; 21(1):5-9. PubMed ID: 1570489
[TBL] [Abstract][Full Text] [Related]
11. Carboxyterminal type I procollagen peptide concentrations in systemic sclerosis: higher levels in early diffuse disease.
Scheja A; Hellmer G; Wollheim FA; Akesson A
Br J Rheumatol; 1993 Jan; 32(1):59-62. PubMed ID: 8422562
[TBL] [Abstract][Full Text] [Related]
12. Serum interleukin-6 level in patients with systemic sclerosis: lack of correlation with aminoterminal propeptide of type III procollagen.
Kucharz EJ; Jonderko G; Rubisz-Brzezinska J; Brzezinska-Wcisło L
Clin Rheumatol; 1995 May; 14(3):380-1. PubMed ID: 7641522
[No Abstract] [Full Text] [Related]
13. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma).
Scheja A; Akesson A; Geborek P; Wildt M; Wollheim CB; Wollheim FA; Vischer UM
Arthritis Res; 2001; 3(3):178-82. PubMed ID: 11299058
[TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of aminoterminal propeptide of type III procollagen and propeptide of human type I procollagen in systemic lupus erythematosus.
Villa-Manzano AI; Gamez-Nava JI; Salazar-Paramo M; Valera-Gonzalez IC; Garcia-Gonzalez A; Garcia-Gonzalez G; Morales-Romero J; Lopez-Olivo A; Galvan-Ramirez LM; Ruiz-Ruvalcaba R; Cardona-Muñoz EG; Gonzalez-Lopez L
Rheumatol Int; 2006 Jun; 26(8):712-6. PubMed ID: 16231121
[TBL] [Abstract][Full Text] [Related]
15. Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement.
Scheja A; Wildt M; Wollheim FA; Akesson A; Saxne T
Rheumatology (Oxford); 2000 Oct; 39(10):1110-3. PubMed ID: 11035131
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis.
Nagy Z; Czirják L
Clin Exp Rheumatol; 2005; 23(2):165-72. PubMed ID: 15895885
[TBL] [Abstract][Full Text] [Related]
17. Serum and urinary aminoterminal type III procollagen peptide in progressive systemic sclerosis: relationship to sclerodermal involvement, serum hyaluronan and urinary collagen metabolites.
Hørslev-Petersen K; Ammitzbøll T; Engström-Laurent A; Bentsen K; Junker P; Asboe-Hansen G; Lorenzen I
J Rheumatol; 1988 Mar; 15(3):460-7. PubMed ID: 3259985
[TBL] [Abstract][Full Text] [Related]
18. Bioactivity of prolactin in systemic sclerosis.
La Montagna G; Meli R; Criscuolo T; D'Angelo S; Valentini G
Clin Exp Rheumatol; 2004; 22(2):145-50. PubMed ID: 15083880
[TBL] [Abstract][Full Text] [Related]
19. Photopheresis in systemic sclerosis: clinical and serological studies using markers of collagen metabolism.
Zachariae H; Bjerring P; Heickendorff L; Møller B; Wallevik K; Angelo H
Acta Derm Venereol; 1993 Oct; 73(5):356-61. PubMed ID: 7904402
[TBL] [Abstract][Full Text] [Related]
20. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
Brkic Z; van Bon L; Cossu M; van Helden-Meeuwsen CG; Vonk MC; Knaapen H; van den Berg W; Dalm VA; Van Daele PL; Severino A; Maria NI; Guillen S; Dik WA; Beretta L; Versnel MA; Radstake T
Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
